Imatinib is actively transported by organic cation transporter-1 (OCT-1) influx transporter, and low OCT-1 activity in diagnostic chronic myeloid leukemia blood mononuclear cells is significantly associated with poor molecular response to imatinib. Herein we report that, in diagnostic chronic myeloid leukemia mononuclear cells and BCR-ABL1+ cell lines, peroxisome proliferator-activated receptor γ agonists (GW1929, rosiglitazone, pioglitazone) significantly decrease OCT-1 activity; conversely, peroxisome proliferator-activated receptor γ antagonists (GW9662, T0070907) increase OCT-1 activity. Importantly, these effects can lead to corresponding changes in sensitivity to BCR-ABL kinase inhibition. Results were confirmed in peroxisome prolifer...
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental ...
BACKGROUND: The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activ...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...
Despite the excellent responses observed in patients with chronic phase (CP) chronic myeloid leukaem...
Active influx of imatinib in chronic myeloid leukemia (CML) cells is mediated by the organic cation ...
BackgroundDespite the excellent responses to imatinib therapy observed in patients with chronic phas...
In CML cells, the functional OCT-1 activity (OA) in mononuclear cells (MNC) from de novo chronic mye...
International audienceWhether cancer is maintained by a small number of stem cells or is composed of...
The functional activity of the organic cation transporter 1 (OCT-1) protein in chronic myeloid leuke...
The introduction of tyrosine kinase inhibitor (TKI) therapy, specifically imatinib, has dramatically...
Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic ...
© 2007 by The American Society of HematologyInterpatient variability in intracellular uptake and ret...
Purpose: Organic cation transporter-1 (OCT-1) activity (OA), a measure of the OCT-1–mediated influx ...
Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib (IC50(i...
Copyright © 2008 American Association for Cancer ResearchPurpose: The organic cation transporter OCT...
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental ...
BACKGROUND: The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activ...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...
Despite the excellent responses observed in patients with chronic phase (CP) chronic myeloid leukaem...
Active influx of imatinib in chronic myeloid leukemia (CML) cells is mediated by the organic cation ...
BackgroundDespite the excellent responses to imatinib therapy observed in patients with chronic phas...
In CML cells, the functional OCT-1 activity (OA) in mononuclear cells (MNC) from de novo chronic mye...
International audienceWhether cancer is maintained by a small number of stem cells or is composed of...
The functional activity of the organic cation transporter 1 (OCT-1) protein in chronic myeloid leuke...
The introduction of tyrosine kinase inhibitor (TKI) therapy, specifically imatinib, has dramatically...
Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic ...
© 2007 by The American Society of HematologyInterpatient variability in intracellular uptake and ret...
Purpose: Organic cation transporter-1 (OCT-1) activity (OA), a measure of the OCT-1–mediated influx ...
Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib (IC50(i...
Copyright © 2008 American Association for Cancer ResearchPurpose: The organic cation transporter OCT...
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental ...
BACKGROUND: The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activ...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...